Journal of Headache and Pain

Papers
(The H4-Index of Journal of Headache and Pain is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis142
CGRP-dependent sensitization of PKC-δ positive neurons in central amygdala mediates chronic migraine116
Using natural language processing to automatically classify written self-reported narratives by patients with migraine or cluster headache88
Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency82
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients67
Pre-pregnancy migraine diagnosis, medication use, and spontaneous abortion: a prospective cohort study64
Trigeminal ganglion itself can be a viable target to manage trigeminal neuralgia51
Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine49
Similarities and differences between SUNCT and SUNA: a cross-sectional, multicentre study of 76 patients in China48
Measuring interictal burden among people affected by migraine: a descriptive survey study46
Debate: Are cluster headache and migraine distinct headache disorders?40
Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results37
Total tenderness score and pressure pain thresholds in persistent post-traumatic headache attributed to mild traumatic brain injury36
Migraine epidemiology and comorbidities in Southern Israel: a clinical database study in a universal health coverage setting35
HMGB1 in the mPFC governs comorbid anxiety in neuropathic pain35
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study35
Tracking the evolution of non-headache symptoms through the migraine attack31
Cerebral blood flow alterations in migraine patients with and without aura: An arterial spin labeling study31
Development and validation of a novel model for characterizing migraine outcomes within real-world data31
Correction: Burden of tension-type headache in the Middle East and North Africa region, 1990-201930
Increased risk of all-cause, Alzheimer’s, and vascular dementia in adults with migraine in Korea: a population-based cohort study29
Microvascular decompression in trigeminal neuralgia - a prospective study of 115 patients29
Headache-related circuits and high frequencies evaluated by EEG, MRI, PET as potential biomarkers to differentiate chronic and episodic migraine: Evidence from a systematic review28
Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis28
Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study27
Longitudinal changes in functional connectivity and pain-induced brain activations in patients with migraine: a functional MRI study pre- and post- treatment with Erenumab27
Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure27
Cardiac cephalalgia: a narrative review and ICHD-3 criteria evaluation27
0.077152967453003